Follistatin-344
Myostatin Antagonist — Muscle Growth Regulator
01
Overview
Follistatin-344 is a recombinant form of follistatin, an autocrine glycoprotein that binds and neutralizes myostatin (GDF-8) and activin. Myostatin is a negative regulator of skeletal muscle mass, and its inhibition has been shown to produce dramatic muscle hypertrophy in research models. Follistatin-344 is studied for muscle wasting, sarcopenia, and neuromuscular disease research.
02
Mechanism of Action
Follistatin binds myostatin (GDF-8) and activin with high affinity, preventing their interaction with ActRII receptors on muscle cells. This removes the inhibitory brake on muscle differentiation and hypertrophy signaling through the Smad2/3 pathway, allowing unopposed myoblast fusion and fiber growth.
03
Research Highlights
Myostatin-knockout and follistatin-overexpression mice show 2-4× muscle mass increases
ALS mouse models demonstrate extended survival and preserved motor function with follistatin gene therapy
Becker muscular dystrophy research shows improved muscle regeneration and reduced fibrosis
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue or Intramuscular (IM) injection. Research protocols use once or twice weekly; preclinical compound.
Dosage Guidelines
Cycle Length
10–15 day courses; research is largely preclinical.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
1 mL added to a 1 mg vial
Concentration
1 mg/mL
Storage
Lyophilized powder: store at -20 °C long-term. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Notes
Follistatin-344 binds and neutralizes myostatin and activin. Preclinical — handle with appropriate research controls.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
Follistatin-344 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
Follistatin-344 Knowledge Graph
Explore how Follistatin-344 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
Follistatin-344 — Common Research Questions
What is Follistatin-344?
Follistatin-344 is a recombinant form of follistatin, an autocrine glycoprotein that binds and neutralizes myostatin (GDF-8) and activin. Myostatin is a negative regulator of skeletal muscle mass, and... Follistatin-344 belongs to the Other research category and is studied for its myostatin antagonist — muscle growth regulator.
How does Follistatin-344 work?
Follistatin binds myostatin (GDF-8) and activin with high affinity, preventing their interaction with ActRII receptors on muscle cells. This removes the inhibitory brake on muscle differentiation and hypertrophy signaling through the Smad2/3 pathway, allowing unopposed myoblast fusion and fiber growth.
What are the key research benefits of Follistatin-344?
Potent myostatin neutralization. Dramatic muscle hypertrophy in research models. Sarcopenia and cachexia research applications. Neuromuscular disease (ALS, DMD) research support. Activin inhibition for reproductive axis modulation. Combined anabolic signaling via multiple TGF-β family members.
What is the molecular structure of Follistatin-344?
Follistatin-344 is a research compound in the Other category. Detailed molecular structure data is being compiled. Refer to primary literature for structural analysis.
What does the research say about Follistatin-344?
Myostatin-knockout and follistatin-overexpression mice show 2-4× muscle mass increases ALS mouse models demonstrate extended survival and preserved motor function with follistatin gene therapy Becker muscular dystrophy research shows improved muscle regeneration and reduced fibrosis These findings are based on preclinical and clinical research. Follistatin-344 is a research compound and these studies do not constitute medical advice.
Is Follistatin-344 FDA approved?
No. Follistatin-344 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does Follistatin-344 belong to?
Follistatin-344 belongs to the Other category, which focuses on a collection of specialized peptides studied across various physiological domains including reproductive health, pigmentation, and growth factor signaling. You can explore more compounds in this category on the Other pillar page.
Related Articles
PT-141: Central Nervous System Activation of Sexual Desire
Understanding how PT-141 differs from PDE5 inhibitors and its Phase III HSDD clinical trial data.
DSIP: Delta Sleep-Inducing Peptide
The discovery, mechanism, and stress-modulation research behind DSIP's sleep-promoting effects.
Kisspeptin: The Gatekeeper of the HPG Axis
How Kisspeptin's pulsatile signaling controls GnRH release and its implications for reproductive research.
Scientific References
Myostatin-knockout and follistatin-overexpression mice show 2-4× muscle mass increases
ALS mouse models demonstrate extended survival and preserved motor function with follistatin gene therapy
Becker muscular dystrophy research shows improved muscle regeneration and reduced fibrosis